There is a lack of cohesive reports on the systemic levels of local anaesthetic after intraperitoneal application. A comprehensive systematic review with no language restriction was conducted. Eighteen suitable articles were identified. Data were compiled and presented according to local anaesthetic agent. Intraperitoneal local anaesthetic has been studied in many different procedures, including open and laparoscopic surgery. A total of 415 patients were included for analysis. There were no cases of clinical toxicity. There were 11 (2.7%) cases with a systemic level above or close to a safe threshold (as determined by the report authors) in three trials utilising intraperitoneal local anaesthetic after laparoscopic cholecystectomy. Intraperitoneal lignocaine doses varied from 100 to 1000 mg, mean Cmax ranged from 1.01 to 4.32 µg/ml and mean Tmax ranged from 15 to 40 minutes. Intraperitoneal bupivacaine doses varied from 50 to 150 mg (weight based doses also reported), mean Cmax ranged from 0.29 to 1.14 µg/ml and mean Tmax ranged from 15 to 60 minutes. Intraperitoneal ropivacaine doses varied from 100 to 300 mg, mean Cmax ranged from 0.66 to 3.76 µg/ml and mean Tmax ranged from 15 to 35 minutes. The addition of adrenaline to intraperitoneal local anaesthetic almost halves systemic levels and prolongs Tmax. Intraperitoneal local anaesthetic results in detectable systemic levels in the perioperative setting. Despite a lack of clinical toxicity, careful attention to dose is still required to prevent potential systemic toxic levels. Clinicians should also consider the addition of adrenaline to intraperitoneal local anaesthetic solutions to further add to the systemic safety profile.
Intraperitoneal local anaesthetic (IPLA) use was first reported in the early 1950s 1, 2 . Over the last two decades, IPLA administration has been investigated more frequently for perioperative analgesia and other anti-inflammatory properties and it is postulated to block visceral pathways when directly applied to the peritoneum. A variety of surgical and gynaecological applications have been utilising IPLA [3] [4] [5] . Several trials, including those in bowel surgery, have indicated that when local anaesthetics (LA) are directly applied to the peritoneal surface at the origin of injury, there is faster resumption of bowel motility, a reduced neuroendocrine response to surgery and reduced opioid and rescue analgesia use when combined with general anaesthesia or regional techniques [6] [7] [8] [9] [10] [11] [12] . There are also additional advantages in terms of prevention of deleterious inflammatory cascade activation in the abdominal cavity after contamination [13] [14] [15] . Therefore, IPLA presents a practical and relatively easy way to block neural 'field' afferents.
The precise site of action of IPLA is not fully understood, although it is likely that there is blockade of free afferent nerve endings in the peritoneum. There are also reports of direct activity of local anaesthetic on smooth muscle cells of the bowel wall [16] [17] [18] and there may be an effect due to systemic uptake of local anaesthetic effect 19, 20 .
While local anaesthetics have a relatively wide safety margin, toxicity may occur if serum levels exceed thresholds. Serious toxicity manifests most commonly by effects on the central nervous and cardiovascular systems 21, 22 . Serum levels of local anaesthetic after non-vascular administration correspond with the vascularity of the tissue (tracheal >intercostal >paracervical >epidural >brachial plexus >sciatic >subcutaneous). The serum levels obtained after relatively common applications in epidural and spinal applications have been well characterised and discussed in the literature 23, 24 . Intravenous studies have also been performed to identify serum toxic levels in volunteers 21, 22, 25 . However, dedicated safety studies measuring serum levels attained after application of different doses and agents intraperitoneally have not been performed. Some studies conducted for other indications have, however, measured serum levels of an individual local anaesthetic at arbitrarily determined doses in patients undergoing this mode of anaesthetic delivery 5, 26, 27 .
New delivery methods of LA such as nebulisers and infusions have been tested to ensure uniform intraperitoneal (IP) coating and prolonged availability after laparoscopy [28] [29] [30] . Hence, IPLA may become more widely used in the future. The aim of this review is to identify studies reporting serum levels of local anaesthetic after intraperitoneal delivery for any indication, and to present these data collectively in an attempt to further understand the characteristics of IP anaesthetic delivery.
MeTHODS Search
A database search was carried out independently by the first two authors (AK, TS). The following databases were searched from the inception of the databases to June 2009: Medline, Cumulative Index to Nursing and Allied Health Literature, Pubmed, Cochrane Controlled Trials Register and embase. The search terms used were: "local anaesth$", "local anesth$", "nerve conduct$", "ropiva$", "bupiva$", "lignoca$", lignoca$", "procaine", "intra-abdominal$", "intraperitoneal", "viscera$", "laparosc$", "peritone$", "coeliosco$", "surg$" "gyne$", "gynae$". Language limitation was not used. Additional articles or abstracts were retrieved by hyperlinks and by manually scrutinising the reference tables of relevant publications. Relevant academic meeting proceedings were searched by the second author.
Selection criteria
All human clinical trials investigating intraabdominal local anaesthetic use, for any indication, with a description of serum local anaesthetic level measurements were included in the review. Animal studies and studies reporting the use of preperitoneal or abdominal wall (incisional) local anaesthetics were excluded. There was no limitation on trial design. Publications in languages other than english were translated with the help of academics at the Faculty of Medical and Health Sciences at the University of Auckland.
All retrieved articles were independently examined by two authors (AK, TS) and any disagreement over inclusion or exclusion was discussed with another author (AGH) and a consensus reached.
Data abstraction
Data were entered by two authors (AK, RV) into tables, based on reported serum measurement data and timeline of local anaesthetic application to the intraperitoneal cavity. This was used to determine the peak serum level (Cmax) and time-to-peak serum level (Tmax). Means and standard deviation were used where available and authors were contacted for additional information when required.
Method of drug detection was also recorded, with deviation from standard techniques reported in the table of results. No attempt was made to model the pharmacokinetics or pharmacodynamics as this would incur significant inaccuracies based on study heterogeneity, differences in detection method, procedures performed and anaesthetic regimens. Simple graphical representation of detected systemic level versus time was carried out if enough data were available to compile mean data over time amongst different trials.
ReSULTS
The QUOROM diagram 31 of the search strategy is presented in Figure 1 . Three trials that reported systemic levels of local anaesthetic after IPLA had to be excluded from analysis due to concomitant extra-peritoneal use of local anaesthetics as well as IPLA (Table 1 ). In two of these trials an infusion system was set up for ongoing pain management postoperatively.
Among 415 patients included for analysis in all the included studies, there were 11 (2.7%) cases of systemic local anaesthetic levels observed with a potential for toxicity (as defined by the publication authors) but no case of clinical toxicity was observed.
Anaesthesia and Intensive Care, Vol. 38, No. 4, July 2010 Lignocaine Nine trials reported the use lignocaine for IPLA and subsequently measured serum results ( Table 2 ). The majority of these were in laparoscopic sterilisation and other gynaecological procedures. Doses used varied from 100 to 1000 mg. Serum levels of lignocaine were detected as early as five minutes after application 32 , with a Tmax ranging from 15 to 40 minutes. With the addition of adrenaline this appeared to be prolonged 32, 33 . Adrenaline changed the serum profile by reducing Cmax and prolonging Tmax by about two-fold respectively 33 .
The concentration time curve of lignocaine after IP bolus administration was reported 19, [32] [33] [34] [35] . Mean Cmax was quite varied (which is to be expected with wide dosing) ranging from 1.01 µg/ml 36 to 4.32 µg/ml 33 . No report of serum or clinical toxicity was found. Figure 2 shows the graphical representation of systemic lignocaine absorption from these trials.
Bupivacaine
Nine trials reported serum bupivacaine levels after IP application (Table 3 ). Five were in laparoscopic cholecystectomy and two were in laparoscopic FIgure 1: QUOROM 31 diagram of search strategy. Note: Some studies used more than one agent hence 22 individual reports were used based on 18 publications. sterilisation, one in diagnostic laparoscopy and one in open upper gastrointestinal tract surgery. One trial was excluded as it did not provide adequate data 37 . Several of these reports used weight-based dosing of IP bupivacaine 7, [38] [39] [40] , while others reported using from 50 to 150 mg in a bolus fashion 37, 41 . All concentration time curves were similar 7, 27, 33, 35, 38, 39, 41 .
Tmax ranged from 15 to 60 minutes after bolus administration overall and Tmax was prolonged in one study when adrenaline was added to the IPLA, going from 30 to 50 minutes with a corresponding Cmax drop to about half of the non-adrenaline group 41 . Doses varied from 50 to 150 mg and a variety of weight-based doses were used ( Table 3 ). Mean Cmax, as would be expected, ranged according to the total dose administered and was reported to be from 0.29 to 1.14 µg/ml after bolus administration. In two studies, potential toxic serum level (as defined by study authors) was reached in two patients who had received 2.25 mg/kg and 125 mg of IP bupivacaine after laparoscopic cholecystectomy with no clinical toxicity observed 27, 39 .
Bupivacaine is known to be highly bound to alpha-1-acid-glycoprotein (AAG) but without significant correlation between plasma levels and AAG levels study 27 . The bupivacaine metabolite 2,6-pipecoloxylidide was first detected in low levels 60 minutes after IP administration 38 . Figure 3 shows the graphical representation of systemic bupivacaine absorption from these trials.
Ropivacaine
Two studies using IP ropivacaine were identified, one in laparoscopic cholecystectomy 42 and one in upper gut and gynaecological laparoscopy 43 (Table  4 ). Two other studies had to be excluded due to concomitant extraperitoneal use of local anaesthetics ( Table 1) .
IP ropivacaine doses varied from 100 to 300 mg in the included studies ( Table 4 ). Cmax varied according to the dose administered, from 0.66 to 3.76 µg/ml, and Tmax was reported in all groups of patients to be between 15 to 35 minutes post application. Free concentrations of ropivacaine were reported and these were approximately 2% of the total concentration, indicating high protein binding 28 . Figure 4 shows the graphical representation of systemic ropivacaine absorption from these trials.
No study was identified which added adrenaline to ropivacaine. Labaille et al 42 reported that eight of 19 patients had potential serum toxicity. However, Question arises whether pain relief is from plasma levels of the agent or local peritoneal effects. Toxicity taken as 10 µg/ml. there were no signs of clinical toxicity in any of the patients. Two had reached this level after the first administration of 150 mg IP ropivacaine and six after the second dose of 150 mg IP ropivacaine (300 mg total). Systemic toxicity was defined in this study by Labaille et al as a serum level >4.0 µg/ml, based on a previous study on healthy adult volunteers who received intravenous infusions of ropivacaine 21 .
Etidocaine
Two studies that used etidocaine for IPLA were identified. However, only one study reported the actual serum levels after IP administration (Table 5) 38 and the other was excluded as noted above 37 . Peak serum level of 0.50 µg/ml was reached 17.7 minutes after IP administration of 2 mg/kg of 1% etidocaine during laparoscopic sterilisation. The time concentration curve was similar to other local anaesthetic agents. There were no reports of clinical toxicity. Etidocaine was absorbed rapidly and was detected in the blood one minute after IP application, as were the metabolites of etidocaine. Graphical representation was not possible.
The effect of the operation
Analysis was carried out to identify the effect of the operation type on the systemic level obtained after IPLA. Due to the wide variability of dose and drugs used in the identified trials, only five trials could be closely matched for this purpose. Three trials used lignocaine, one was in laparoscopic cholecystectomy where 400 mg was the dose administered 19 and the other two in laparoscopic sterilisation where 500 mg was administered 4, 26 . Figure  5 shows that the systemic levels obtained were higher in the laparoscopic cholecystectomy trial despite a smaller dose being used.
Two other trials utilising bupivacaine were matched. One trial reported 125 mg dose after laparoscopic cholecystectomy 27 and the other 100 mg in laparoscopic steralisation 44 . Figure 6 shows that the systemic levels were higher at all time points in the laparoscopic cholecystectomy trial.
Of interest is the fact that all the potential serum toxic levels reported have been in laparoscopic cholecystectomy, with two studies utilising postdissection IPLA 27, 39 and one study utilising pre-and post-dissection IPLA 42 .
The effect of adrenaline
The effect of adrenaline on systemic absorption of bupivacaine was investigated in two trials: one study was in diagnostic laparoscopy 33 and the other in laparoscopic cholecystectomy 41 . The first study by Narchi et al showed that the addition of adrenaline to IPLA halved the Cmax and prolonged Tmax. Graphical presentation was possible using data from the second study by Scheinin et al. Figure 7 shows that the addition of 150 µg of adrenaline to the IPLA solution containing 150 mg bupivacaine reduced the Cmax to almost half.
DISCUSSION
This systematic review summarises the available literature on serum local anaesthetic levels reached after IPLA administration. Most of the data pertain to the use of IP lignocaine and bupivacaine and estimates of Tmax and Cmax were presented based on the reported literature. Importantly, there was no case of clinical toxicity reported in any of these trials.
There appear to be clinical benefits to be gained from IPLA administration such as reduced pain, reduced opioid use and faster resumption of bowel function as has been reported in meta-analyses [45] [46] [47] . However, no research specifically addressing dosing or safety has been identified, with most trials looking primarily at clinical outcomes after IPLA administration.
Toxicity
This review did not find any reports of clinical (cardiovascular or neurological) toxicity following IPLA. This is despite three reports of serum levels having reached potential toxic levels 27, 39, 42 . First, in the study by Labaille et al, after administration of the first dose of 150 mg IP ropivacaine, two patients reached levels greater than 4 µg/ml. After the second dose given after dissection (i.e. 300 mg IP ropivacaine in total) six patients reached levels greater than 4 µg/ml. It is unclear if these six patients included the first two patients who had high levels after the first dose. Regardless, this is of concern as at serum level greater than 4 µg/ml, CNS toxicity has been observed in volunteers receiving intravenous infusion of ropivacaine 21 . Second, in a study by Raetzel et al, free serum bupivacaine exceeded the threshold for toxicity (reported as being 0.24 mg/l) in one patient who was administered 125 mg of IP bupivacaine. No other information was provided, such as the patient's weight or possibility of inadvertent intravascular application to the raw operative bed. Third, in the study by Fuhrer et al, one patient exceeded the total serum bupivacaine threshold of 1.6 µg/ml, quoted as the toxic threshold by the authors, after being administered 2.25 mg/kg of IP bupivacaine without any clinical effects. These cases probably represent outliers but should remain of some concern.
The reason for the absence of clinical toxicity, despite potential toxic thresholds being reached, is unclear, but this is likely to be a result of several factors. First, the toxic levels quoted by many authors are based on studies carried out in nonmedicated individuals under experimental settings. In the clinical setting where these trials were carried out, patients were often under the influence of sedative medications as part of the anaesthetic regimen. Medications such as benzodiazepines and barbiturates increase the neurological threshold of toxicity from local anaesthetics [48] [49] [50] [51] .
It is also known that general anaesthesia changes the whole body and regional pharmacokinetics of local anaesthetic agents 52, 53 . In addition, there is an inflammatory response after surgery, leading to the increase in serum acute phase proteins such as alpha-1-acid glycoproteins (AAG). Local anaesthetics are mostly bound to AAG. The amount varies from 60 to 80% for lignocaine 54 and higher than 90% for bupivacaine and ropivacaine 55, 56 , and therefore there may be a reduced free fraction of local anaesthetic after surgical insult due to the rising AAG. AAG has a particularly high affinity and low capacity for bupivacaine and ropivacaine and plays a major role in binding at concentrations less than 5 µg/ml 55 . The clinical consequences of this were confirmed in a study by Wulf et al 57 , which demonstrated that as plasma AAG levels rose in the postoperative period, there was a decrease in the free fraction of bupivacaine from 6.3 to 5.4%.
Another strategy to prevent toxic serum levels is the addition of adrenaline to local anaesthetic solution to increase length of action and reduce systemic absorption 58 . Narchi et al have reported that the Tmax and Cmax obtained after IP administration of plain lignocaine compares with that reported via other extra-vascular routes such as epidural and axillary infiltration 25, 33 . This indicates that there is relatively little first pass effect from the peritoneal cavity despite extensive drainage into the portal circulation. The administration of adrenaline to the IP drug significantly increased Tmax and decreased Cmax without any side-effects and therefore this technique may provide additional safety margins 32, 33, 41 .
In this study we were able to show that there may be a difference in the systemic levels of IPLA based on the type of operation performed. For example, after laparoscopic cholecystectomy, serum levels were higher when compared to laparoscopic sterilisation when similar doses were administered. This may be due to the extent of dissection and the availability of raw surfaces, which may increase the absorption rate of the drug. Sterilisation has little intraperitoneal dissection associated, whereas in cholecystectomy, an intraperitoneal wound subsequently referred to as the 'gallbladder bed' in the literature is created when the organ is resected away from the liver. There is also greater manipulation and peritoneal dissection involved.
There is considerable variability in accepted upper limits for toxicity threshold. Serum levels at which lignocaine toxicity results in seizures is generally quoted to be above 15 µg/ml 59 . Cruickshank et al reported the threshold for lignocaine toxicity at 9 to 10 µg/ml 60 . Some authors have suggested 2 µg/ml for bupivacaine and others up to 4 or 5 µg/ml 7, 22, [61] [62] [63] [64] . In the study by Fuhrer et al 39 , the very conservative lower threshold of 1.6 µg/ml as being toxic was set by the authors. Based on our search, we found one report of toxicity occurring at concentrations as low as 1.1 µg/ml 65. However, even the mildest toxic symptoms are unlikely to appear below plasma levels of 1.6 µg/ml 66, 67 . Gupta et al used levobupivacaine in one trial and reported total and free medians of 2.2 and 0.04 µg/ml after 23 hours of infusion respectively, without any clinical toxicity 68 . The authors reported that that there are no agreed data on toxic levels of levobupivacaine. However, in one study, central nervous effects were seen at a total mean level of 2.62 µg/ml 69 . In another study by Gupta et al 28 , ropivacaine was used, due to its favourable cardiovascular toxic profile 70, 71 . The highest ropivacaine level (1.8 µg/ml total serum level) was well below toxicity level as shown in healthy nonmedicated individuals to be 4.3 mg/ml in arterial blood 21 and this threshold is generally agreed upon 72 .
Pharmacokinetics and profile
Studies utilising IPLA demonstrate that peak levels of serum bupivacaine occur somewhere between 10 and 39 minutes after intraperitoneal administration. early peak plasma levels were seen at six minutes for etidocaine 27 . The Tmax observed after lignocaine instillation occurs at 15 to 40 minutes and 30 to 35 minutes for ropivacaine. These results indicate that local anaesthetic placed intraperitoneally will be absorbed rapidly in the blood stream 38 . However, ongoing monitoring is also warranted as late peaks did occur as seen in some patients at 30 minutes for etidocaine and 60 minutes for bupivacaine.
In this review we have seen that the concentration time curve of total serum levels for all the different local anaesthetic agents follows the expected model of bolus dosing. This indicates that there are similarities between IP administration and other more common routes such as that seen in the epidural blockade 24, 25, 57, 73 . Absorption may be into the portal circulation or systemic circulation and the degree of this may be dependent on the anatomical location of instillation (pelvic instillation versus upper abdomen) and a product of concentration effect. However, the first pass effect seems to be minor or irrelevant, as discussed above, despite a metabolism that seems to occur soon after application. For example, metabolites of etidocaine were seen in the blood one minute after application to the fallopian tubes in one study 38 . This does not seem to impact on the clearance or uptake of the drug significantly. Fuhrer et al used pharmacokinetic models to estimate the clearance of intraperitoneal bupivacaine to be 10.2±5.6 ml/min/kg based on the study of 12 patients receiving 2.25 mg/kg of intraperitoneal bupivacaine at the end of laparoscopic cholecystectomy 39 .
This systematic review has weaknesses that should be pointed out. First, due to the lack of individually reported data, we were unable to perform any pharmacodynamic or kinetic modelling. This would have been particularly useful in order to assimilate this technique to other routine techniques in terms of uptake and disposition models. Hence, we were limited by the study heterogeneity present and the lack of adequate pharmacological attendance to this issue in the presented studies. However, this is the first such review on this topic and we believe that there is valuable information presented for surgeons and anaesthetists. The use of IPLA is likely to gain more favour as new techniques such as spraying, infusing and humidifying LA in the peritoneal cavity are being developed 30, 74, 75 .
In conclusion, the use of IPLA is associated with rapidly detectable high levels in the serum, and it would appear that absorption of IPLA into the systemic circulation seems to be similar to LA application for other indications such as epidural and peripheral nerve blockade. Although no case of clinical toxicity was detected, careful attention should be paid to the dose and timing of IPLA with regard to dissection, to prevent high or potentially toxic systemic levels. The addition of adrenaline to the solution to prolong Tmax and lowering Cmax increases the safety profile. This information is very relevant for planning future trials evaluating safety of IPLA use in the perioperative setting.
